Setbacks and Opportunities in Disease-Modifying Therapies in Alzheimer Disease
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DMTs are treatments that postpone, moderate, or even reverse the evolution of an illness by addressing its underlying cause.
“DMTs are treatments that postpone, moderate, or even reverse the evolution of an illness by addressing its underlying cause.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [59]
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461 · see citing works
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · see citing works
The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860 · see citing works
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697 · see citing works
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
Wang, J., Logovinsky, V., Hendrix, S. B., Stanworth, S. H., Perdomo, C., Xu, L., Dhadda, S., Do, I., Rabe, M., Luthman, J., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312383 · Cited by 160 · see citing works
Putting the Alzheimer's cognitive test to the test I: Traditional psychometric methods
Hobart, J. C., Cano, S., Posner, H. B., Selnes, O. A., Stern, Y., Thomas, R. G., Zajicek, J., & Initiative, A. D. N. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.08.005 · Cited by 48 · see citing works
The Limitations of Using Cognitive Cutoff Scores for Enrollment in Alzheimer Trials
Patrick, R. E., Hobbs, K., Mathias, L., Harper, D. G., & Forester, B. P. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.02.014 · Cited by 4 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer’s disease
Sprugnoli, G., Munsch, F., Cappon, D., Paciorek, R., Macone, J., Connor, A., El Fakhri, G., Salvador, R., Ruffini, G., Donohoe, K., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00922-4 · Cited by 99 · see citing works
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works
“DMTs consist of three primary components: therapy, sick-Molecules ness, and modification [37,59].”
Background
- Authors
- Forester, B. P., Patrick, R. E., & Harper, D. G.
- Affiliations
- Harvard University (US)
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2020-01-01
- Volume
- 77
- Issue
- 1
- Pages
- 7
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2974353331
- Cited by
- 9
- References
- 8
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 1
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, disease-modifying therapy, clinical trials, anti-amyloid therapy, anti-tau therapy, clinical trial failure, drug development
- MeSH terms
- Alzheimer Disease, Humans, Amyloid beta-Peptides, Treatment Failure, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
